News

ThromboGenics has completed the enrollment of the second Phase III trial evaluating Microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both in

Naurex has initiated a Phase I clinical trial of its GLYX-13 and has successfully dosed the first subjects in the study. GLYX-13, a glycine site functional partial agonist

Diagnostic Nano Technology (DNA), a subsidiary of Avisio, has reported that with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that

Makefield Therapeutics has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield’s biodegradable Hybrid Nanoparticles, a new drug delivery

Keryx Biopharmaceuticals, (Keryx) has initiated Phase 3 registration clinical trial for KRX-0401 (perifosine), a PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial, entitled, ‘A

Takeda Pharmaceutical (Takeda) and Pfizer have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in the country.

Neptune Technologies & Bioressources (Neptune) announces additional preclinical research results on its Acasti Pharma (Acasti) drug development program. Acasti announces the results of additional preclinical research designed to

The Medicines has reported that it is voluntarily recalling eleven lots of Cleviprex (clevidipine butyrate) injectable emulsion due to the potential presence of visible particulate matter which has

Unilife Medical Solutions (Unilife) has signed agreements for the construction of its new global headquarters and commercial production facility in York, Pennsylvania. The medical device production facility will